메뉴 건너뛰기




Volumn 26, Issue 6, 2012, Pages 357-361

The US approach to biosimilars: The long-awaited FDA approval pathway

Author keywords

Biological products; Regulatory process; Therapeutic substitution

Indexed keywords

BIOSIMILAR AGENT;

EID: 84868121118     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11635830-000000000-00000     Document Type: Article
Times cited : (28)

References (23)
  • 1
    • 79961107025 scopus 로고    scopus 로고
    • online]. Available from URL: Accessed 2012 May 31]
    • Biologics Price Competition and Innovation Act (2009) [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceCompliance Regulatory Information/UCM216146.pdf [Accessed 2012 May 31]
    • (2009) Biologics Price Competition.Innovation Act
  • 2
    • 84876082884 scopus 로고    scopus 로고
    • 355(b)(2) and 355(j)) [online]. Available from URL [Accessed 2012 May 31]
    • See section 505(b)(2) and 505(j) of the FD&C Act (21 U.S.C. 355(b)(2) and 355(j)) [online]. Available from URL: http://www.fda.gov [Accessed 2012 May 31]
    • See Section 505(b)(2) and 505(j) of the FD&C Act (21 U.S.C
  • 3
    • 33644952525 scopus 로고    scopus 로고
    • Committee For Medicinal Products For Human Use (CHMP. CHMP43704 [online]. Available From URL: [Accessed 2012 April 27
    • Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products. CHMP/437/04 [online]. Available from URL: http://www.emea.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003517.pdf [Accessed 2012 April 27]
    • Guideline On Similar Biological Medicinal Products
  • 4
    • 67549097000 scopus 로고    scopus 로고
    • Regulatory aspects of biosimilars in Europe
    • Zuniga L, Calvo B. Regulatory aspects of biosimilars in Europe. Trends Biotechnol 2009; 27: 385-7
    • (2009) Trends Biotechnol , vol.27 , pp. 385-387
    • Zuniga, L.1    Calvo, B.2
  • 7
    • 84876095755 scopus 로고    scopus 로고
    • Committee For Medicinal Products For Human Use (CHMP. EMACHMPBMWP5726432011[online]. Available From URL: [Accessed 2012 May 31]
    • Committee for Medicinal Products for Human Use (CHMP). Concept paper on the revision of the guideline on similar biological medicinal product. EMA/CHMP/BMWP/572643/2011[online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2011/11/ WC500117987.pdf [Accessed 2012 May 31]
    • Concept Paper On The Revision Of The Guideline On Similar Biological Medicinal Product
  • 10
    • 84876081314 scopus 로고    scopus 로고
    • Committee For Medicinal Products For Human Use (CHMP. EMEACHMPBMWP102046 [online]. Available from URL: [Accessed 2012 May 31]
    • Committee for Medicinal Products for Human Use (CHMP). Non-clinical and clinical development of similar medicinal products containing recombinant interferon alpha. EMEA/CHMP/BMWP/102046/2006 [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Sci entific-guideline/2009/ 09/WC500003930.pdf [Accessed 2012 May 31]
    • (2006) Non-Clinical And Clinical Development Of Similar Medicinal Products Containing Recombinant Interferon Alpha
  • 11
    • 84876089219 scopus 로고    scopus 로고
    • Committee For Medicinal Products For Human Use (CHMP. EMEA CHMPBMWP30163608 [online]. Available From URL:[Accessed 2012 May 31]
    • Committee for Medicinal Products for Human Use (CHMP). Similar biological medicinal products containing recombinant erythropoietins. EMEA/ CHMP/BMWP/301636/08 [online]. Available from URL: http://www. ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/04/ WC500089474.pdf [Accessed 2012 May 31]
    • Similar Biological Medicinal Products Containing Recombinant Erythropoietins
  • 14
    • 84871481289 scopus 로고    scopus 로고
    • Committee For Medicinal Products For Human Use (CHMP. EMACHMPBMWP4035432010 [online]. Available From URL: [Accessed 2012 May 31]
    • Committee for Medicinal Products for Human Use (CHMP). Similar biological medicinal products containing monoclonal antibodies: Non-clinical and clinical issues. EMA/CHMP/BMWP/403543/2010 [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2012/06/WC500128686.pdf [Accessed 2012 May 31]
    • Similar Biological Medicinal Products Containing Monoclonal Antibodies: Non-clinical And Clinical Issues
  • 15
    • 84876070851 scopus 로고    scopus 로고
    • Committee For Medicinal Products For Human Use (CHMP. CHMPBMWP6712922010 [online]. Available From URL: [Accessed 2012 May 31]
    • Committee for Medicinal Products for Human Use (CHMP). Similar biological medicinal products containing recombinant follicle stimulation hormone. CHMP/BMWP/671292/2010 [online]. Available from URL: http:// www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2011/ 11/WC500117986.pdf [Accessed 2012 May 31]
    • Similar Biological Medicinal Products Containing Recombinant Follicle Stimulation Hormone
  • 16
    • 84876089219 scopus 로고    scopus 로고
    • Committee For Medicinal Products For Human Use (CHMP. CHMPBMWP 6520002010 [online]. Available From URL: [Accessed 2012 May 31]
    • Committee for Medicinal Products for Human Use (CHMP). Similar biological medicinal product containing interferon beta. CHMP/BMWP/ 652000/2010 [online]. Available from URL: http://www.ema.europa.eu/docs/ en-GB/document-library/ Scientific-guideline/2012/01/WC500120652.pdf [Accessed 2012 May 31]
    • Similar Biological Medicinal Product Containing Interferon Beta
  • 17
    • 84876084861 scopus 로고    scopus 로고
    • Guidance For Industry: Scientific Considerations In Demonstrating Biosimilarity To A Reference Product February 2012 [online].Available FromURL:[Accessed 2012May 31]
    • Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: Scientific considerations in demonstrating biosimilarity to a reference product, February 2012 [online].Available fromURL: http://www.fda.gov/Drugs/DevelopmentApproval Process/HowDrugsareDevelopedandApproved/ApprovalApplications/Therapeu ticBiologicApplications/Biosimilars/default.htm [Accessed 2012May 31]
    • Center For Drug Evaluation And Research (CDER) Center For Biologics Evaluation And Research (CBER
  • 18
    • 84876084861 scopus 로고    scopus 로고
    • Guidance For Industry: Quality Considerations In Demonstrating Biosimilarity To A Reference Protein Product February 2012 [online]. Available From URL: [Accessed 2012 May 31]
    • Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product, February 2012 [online]. Available from URL:http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Approval Applications/TherapeuticBiologicApplications/Biosimilars/default.htm [Accessed 2012 May 31]
    • Center For Drug Evaluation And Research (CDER) Center For Biologics Evaluation And Research (CBER
  • 19
    • 84874151018 scopus 로고    scopus 로고
    • [online]. Available from URL Questions And Answers Regarding Implementation Of The Biologics Price Competition And Innovation Act Of [Accessed 2012 May 31]
    • Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009 [online]. Available from URL: http://www.fda.gov/Drugs/Development ApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplica tions/ TherapeuticBiologicApplications/Biosimilars/default.htm [Accessed 2012 May 31]
    • (2009) Center For Drug Evaluation And Research (CDER) Center For Biologics Evaluation And Research (CBER
  • 20
    • 34548841437 scopus 로고    scopus 로고
    • Biotechs go generic: The same but different
    • DOI 10.1038/449274a, PII 449274A
    • Ledford H. Biotechs go generic: The same but different. Nature 2007; 449: 274-6 (Pubitemid 47443456)
    • (2007) Nature , vol.449 , Issue.7160 , pp. 274-276
    • Ledford, H.1
  • 21
    • 84876086466 scopus 로고    scopus 로고
    • online]. Available from URL: [Accessed 2012 May 31]
    • Gatyas G. Gobal biologics spending (2010) [online]. Available from URL: https://www.brainshark.com/imshealth/vu?pi=zGBzFL1RkzyjTz00 [Accessed 2012 May 31]
    • (2010) Gobal Biologics Spending
    • Gatyas, G.1
  • 22
    • 77955636779 scopus 로고    scopus 로고
    • Biosimilars: Pharmacovigilance and risk management
    • Zuniga L, Calvo B. Biosimilars: Pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf 2010; 19: 661-9
    • (2010) Pharmacoepidemiol Drug Saf , vol.19 , pp. 661-669
    • Zuniga, L.1    Calvo, B.2
  • 23
    • 79961116944 scopus 로고    scopus 로고
    • Developing the nation's biosimilars program
    • Kozlowski S, Woodcock J, Midthun K, et al. Developing the nation's biosimilars program. N Engl J Med 2011; 365: 385-8
    • (2011) N Engl J Med , vol.365 , pp. 385-388
    • Kozlowski, S.1    Woodcock, J.2    Midthun, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.